SEC Info - Cryo Cell International Inc. - ‘10-Q’ for 8/31/22

SEC Info℠

Home

Help

Please Sign In

Cryo Cell International Inc. – ‘10-Q’ for 8/31/22 – ‘EX-31.3’

On: Monday, 10/17/22, at 8:31pm ET · As of: 10/18/22 · For: 8/31/22 · Accession #: 950170-22-19626 · File #: 1-40767

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/18/22  Cryo Cell International Inc.      10-Q        8/31/22   74:15M                                    Donnelley … Solutions/FA

Quarterly Report — Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   3.31M 
 2: EX-10.5     Material Contract                                   HTML   1.73M 
 3: EX-10.6     Material Contract                                   HTML    410K 
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     28K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     28K 
 6: EX-31.3     Certification -- §302 - SOA'02                      HTML     28K 
 7: EX-32.1     Certification -- §906 - SOA'02                      HTML     27K 
13: R1          Cover Page                                          HTML     74K 
14: R2          Consolidated Balance Sheets                         HTML    157K 
15: R3          Consolidated Balance Sheets (Parenthetical)         HTML     44K 
16: R4          Consolidated Statements of Income                   HTML    105K 
17: R5          Consolidated Statements of Cash Flows               HTML    127K 
18: R6          Consolidated Statements of Stockholders' (Deficit)  HTML     66K 
                Equity                                                           
19: R7          Consolidated Statements of Stockholders' (Deficit)  HTML     24K 
                Equity (Parenthetical)                                           
20: R8          Description of Business, Basis of Presentation and  HTML    339K 
                Significant Accounting Policies                                  
21: R9          Segment Reporting                                   HTML    266K 
22: R10         Inventory                                           HTML     62K 
23: R11         Intangible Assets                                   HTML    101K 
24: R12         Notes Payable                                       HTML    139K 
25: R13         Income per Common Share                             HTML    103K 
26: R14         Stockholders' Equity                                HTML    296K 
27: R15         License Agreements                                  HTML     29K 
28: R16         Commitments and Contingencies                       HTML     42K 
29: R17         Share Repurchase Plan                               HTML     35K 
30: R18         Leases                                              HTML    110K 
31: R19         Patent Option and Technology License Agreement      HTML     70K 
32: R20         Description of Business, Basis of Presentation and  HTML    366K 
                Significant Accounting Policies (Policies)                       
33: R21         Description of Business, Basis of Presentation and  HTML    234K 
                Significant Accounting Policies (Tables)                         
34: R22         Segment Reporting (Tables)                          HTML    258K 
35: R23         Inventory (Tables)                                  HTML     61K 
36: R24         Intangible Assets (Tables)                          HTML     96K 
37: R25         Notes Payable (Tables)                              HTML    110K 
38: R26         Income per Common Share (Tables)                    HTML     96K 
39: R27         Stockholders' Equity (Tables)                       HTML    245K 
40: R28         Leases (Tables)                                     HTML    114K 
41: R29         Description of Business, Basis of Presentation and  HTML    104K 
                Significant Accounting Policies - Additional                     
                Information (Detail)                                             
42: R30         Description of Business, Basis of Presentation and  HTML     28K 
                Significant Accounting Policies - Additional                     
                Information 1 (Detail)                                           
43: R31         Description of Business, Basis of Presentation and  HTML     33K 
                Significant Accounting Policies - Schedule of                    
                Assets and Liabilities From Contracts With                       
                Customers (Detail)                                               
44: R32         Description of Business, Basis of Presentation and  HTML     42K 
                Significant Accounting Policies - Schedule of                    
                Change in Assets and Liabilities From Contracts                  
                With Customers (Detail)                                          
45: R33         Description of Business, Basis of Presentation and  HTML     55K 
                Significant Accounting Policies - Financial Assets               
                and Liabilities Measured at Fair Value on                        
                Recurring Basis (Detail)                                         
46: R34         Segment Reporting - Additional Information          HTML     24K 
                (Detail)                                                         
47: R35         Segment Reporting - Summary of Net Revenue, Cost    HTML     68K 
                of Sales, Depreciation and Amortization, Operating               
                Profit, and Interest Expense and Assets by Segment               
                (Detail)                                                         
48: R36         Inventory - Additional Information (Detail)         HTML     24K 
49: R37         Inventory - Components of Inventory (Detail)        HTML     36K 
50: R38         Intangible Assets - Schedule of Intangible Assets   HTML     51K 
                (Detail)                                                         
51: R39         Intangible Assets - Additional Information          HTML     25K 
                (Detail)                                                         
52: R40         Notes Payable - Additional Information (Detail)     HTML    117K 
53: R41         Notes Payable - Schedule of Note Payable            HTML     39K 
                Obligation (Detail)                                              
54: R42         Notes Payable - Summary of Interest Expense on      HTML     35K 
                Note Payable (Detail)                                            
55: R43         Income per Common Share - Calculation of Basic and  HTML     58K 
                Diluted Net Income per Common Share (Detail)                     
56: R44         Income per Common Share - Additional Information    HTML     25K 
                (Detail)                                                         
57: R45         Stockholders' Equity - Additional Information       HTML    153K 
                (Detail)                                                         
58: R46         Stockholders' Equity - Fair Value of Options        HTML     33K 
                Granted (Detail)                                                 
59: R47         Stockholders' Equity - Stock Option Activity        HTML     65K 
                (Detail)                                                         
60: R48         Stockholders' Equity - Significant Option Groups    HTML     67K 
                Outstanding and Exercisable Option and its Price                 
                and Contractual Life (Detail)                                    
61: R49         Stockholders' Equity - Summary of Non-Vested        HTML     40K 
                Options (Detail)                                                 
62: R50         License Agreements - Additional Information         HTML     30K 
                (Detail)                                                         
63: R51         Commitments and Contingencies - Additional          HTML     56K 
                Information (Detail)                                             
64: R52         Share Repurchase Plan - Additional Information      HTML     42K 
                (Detail)                                                         
65: R53         Leases - Summary of Lease Assets and Liabilities    HTML     31K 
                (Detail)                                                         
66: R54         Leases - Summary of Maturity of Company's Lease     HTML     35K 
                Liabilities (Detail)                                             
67: R55         Leases - Summary of Remaining Lease Term and        HTML     27K 
                Discount Rates (Detail)                                          
68: R56         Leases - Summary of Supplemental Cash Flow          HTML     25K 
                Information Related to Leases (Detail)                           
69: R57         Patent Option and Technology License Agreement -    HTML    116K 
                Additional Information (Detail)                                  
72: XML         IDEA XML File -- Filing Summary                      XML    132K 
70: XML         XBRL Instance -- ccel-20220831_htm                   XML   3.70M 
71: EXCEL       IDEA Workbook of Financial Reports                  XLSX    162K 
 8: EX-101.CAL  XBRL Calculations -- ccel-20220831_cal               XML    158K 
 9: EX-101.DEF  XBRL Definitions -- ccel-20220831_def                XML    772K 
12: EX-101.LAB  XBRL Labels -- ccel-20220831_lab                     XML   1.51M 
11: EX-101.PRE  XBRL Presentations -- ccel-20220831_pre              XML   1.03M 
10: EX-101.SCH  XBRL Schema -- ccel-20220831                         XSD    204K 
73: JSON        XBRL Instance as JSON Data -- MetaLinks              441±   685K 
74: ZIP         XBRL Zipped Folder -- 0000950170-22-019626-xbrl      Zip    622K

‘EX-31.3’ — Certification — §302 – SOA’02

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

EX-31.3

EXHIBIT 31.3

CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, Jill M. Taymans, certify that:

I have reviewed this quarterly report on Form 10-Q of Cryo-Cell International, Inc. (the “Registrant”);

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The Registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d – 15(f)) for the Registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting;

The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.


Dated: October 17, 2022			/s/ *Jill M. Taymans*
			Jill M. Taymans

Dates Referenced Herein and Documents Incorporated by Reference

This ‘10-Q’ Filing	Date	Other Filings

Filed as of:	10/18/22	NT 10-Q
Filed on:	10/17/22	NT 10-Q
For Period end:	8/31/22	NT 10-Q
		List all Filings

3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/28/24  Cryo Cell International Inc.      10-K       11/30/23   93:12M                                    Donnelley … Solutions/FA
10/12/23  Cryo Cell International Inc.      10-Q        8/31/23   70:12M                                    Donnelley … Solutions/FA
 2/28/23  Cryo Cell International Inc.      10-K       11/30/22   97:15M                                    Donnelley … Solutions/FA

4 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/13/22  Cryo Cell International Inc.      10-Q        2/28/22   75:10M                                    Donnelley … Solutions/FA
 3/16/22  Cryo Cell International Inc.      8-K:1,8,9   3/14/22   12:1.2M                                   Donnelley … Solutions/FA
12/11/18  Cryo Cell International Inc.      8-K:5,9    12/06/18    2:106K                                   Donnelley … Solutions/FA
 7/19/02  Cryo Cell International Inc.      10QSB       5/31/02    3:84K                                    Donnelley … Solutions/FA

↑Top

Filing Submission 0000950170-22-019626 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)